Compare Stocks → [Urgent!] Generational Wealth Gameplan (From Crypto 101 Media) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NYSE:IKTNASDAQ:ONVONASDAQ:RUBYNASDAQ:TTNP Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeIKTInhibikase Therapeutics$2.13$2.26$0.79▼$4.35$13.77M1.1937,469 shs37,008 shsONVOOrganovo$1.12-2.6%$1.03$0.89▼$2.23$11.55M0.912.87 million shs544,306 shsRUBYRubius Therapeutics$0.06+2.7%$0.04$0.00▼$0.38$5.16M2.591.15 million shs755,800 shsTTNPTitan Pharmaceuticals$7.10-2.2%$7.34$5.00▼$16.60$6.63M1.3311,357 shs2,555 shs7 Stocks to Buy And Hold ForeverClick the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceIKTInhibikase Therapeutics-1.39%-2.74%+5.97%+22.41%-38.68%ONVOOrganovo-2.61%+8.74%+0.90%+7.69%-48.15%RUBYRubius Therapeutics0.00%0.00%0.00%0.00%+154.18%TTNPTitan Pharmaceuticals-2.17%-3.27%-3.14%+15.26%-55.61%The “Perfect Storm” for Gold (Ad)Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.Click here now to download the free Precious Metals Buying Guide!MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationIKTInhibikase Therapeutics0.9751 of 5 stars3.50.00.00.00.01.70.6ONVOOrganovo0.4403 of 5 stars0.03.00.00.02.90.01.3RUBYRubius TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/ATTNPTitan PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/AAnalyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceIKTInhibikase Therapeutics3.00Buy$27.001,167.61% UpsideONVOOrganovoN/AN/AN/AN/ARUBYRubius TherapeuticsN/AN/AN/AN/ATTNPTitan PharmaceuticalsN/AN/AN/AN/ACurrent Analyst RatingsLatest ONVO, TTNP, RUBY, and IKT Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails3/5/2024IKTInhibikase TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$27.00(Data available from 4/18/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookIKTInhibikase Therapeutics$260K53.09N/AN/A$1.78 per share1.20ONVOOrganovo$370K30.39N/AN/A$1.76 per share0.64RUBYRubius TherapeuticsN/AN/AN/AN/A$0.17 per shareN/ATTNPTitan Pharmaceuticals$180K35.89N/AN/A$8.82 per share0.80Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateIKTInhibikase Therapeutics-$19.03M-$3.56N/AN/AN/A-5,886.15%-107.54%-91.82%5/20/2024 (Estimated)ONVOOrganovo-$17.26M-$2.17N/AN/AN/AN/A-182.88%-138.52%7/11/2024 (Estimated)RUBYRubius Therapeutics-$179.67MN/A0.00∞N/AN/AN/AN/AN/ATTNPTitan Pharmaceuticals-$5.57M-$8.20N/A∞N/A-2,014.71%-165.90%-105.75%5/20/2024 (Estimated)Latest ONVO, TTNP, RUBY, and IKT EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails3/27/2024Q4 2023IKTInhibikase Therapeutics-$0.78-$0.63+$0.15-$0.63N/AN/A 2/8/2024Q3 2024ONVOOrganovo-$0.41-$0.40+$0.01-$0.40$0.08 million$0.01 millionDividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthIKTInhibikase TherapeuticsN/AN/AN/AN/AN/AONVOOrganovoN/AN/AN/AN/AN/ARUBYRubius TherapeuticsN/AN/AN/AN/AN/ATTNPTitan PharmaceuticalsN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioIKTInhibikase TherapeuticsN/A4.134.13ONVOOrganovoN/A3.673.67RUBYRubius TherapeuticsN/AN/AN/ATTNPTitan PharmaceuticalsN/A5.555.55OwnershipInstitutional OwnershipCompanyInstitutional OwnershipIKTInhibikase Therapeutics3.81%ONVOOrganovo8.23%RUBYRubius TherapeuticsN/ATTNPTitan Pharmaceuticals31.49%Insider OwnershipCompanyInsider OwnershipIKTInhibikase Therapeutics20.30%ONVOOrganovo4.00%RUBYRubius Therapeutics5.30%TTNPTitan Pharmaceuticals24.93%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableIKTInhibikase Therapeutics86.48 million5.16 millionNot OptionableONVOOrganovo1810.04 million9.64 millionOptionableRUBYRubius Therapeutics690.48 million85.69 millionNot OptionableTTNPTitan Pharmaceuticals4910,000686,000OptionableONVO, TTNP, RUBY, and IKT HeadlinesSourceHeadlineTitan Pharmaceuticals (NASDAQ:TTNP) Now Covered by StockNews.comamericanbankingnews.com - April 15 at 2:14 AMLexeo Therapeutics (NASDAQ:LXEO) and Titan Pharmaceuticals (NASDAQ:TTNP) Critical Contrastamericanbankingnews.com - April 13 at 1:30 AM2005 Nissan Titanautoblog.com - March 25 at 4:09 AMTitan Pharmaceuticals Inc (TTNP)uk.investing.com - March 2 at 9:17 AMTitan Pharmaceuticals, Inc. (TN70.F)au.finance.yahoo.com - February 20 at 2:08 PMTitan Pharmaceuticals Inc TTNPmorningstar.com - February 3 at 2:27 PMTitan Pharmaceuticals, Inc.: Titan Pharmaceuticals Fully Compliant With NASDAQ Listing Criteriafinanznachrichten.de - January 26 at 9:07 PMTitan Pharmaceuticals Fully Compliant With NASDAQ Listing Criteriafinance.yahoo.com - January 25 at 7:32 PMTitan Pharma Stock (NASDAQ:TTNP) Dividends: History, Yield and Datesbenzinga.com - January 10 at 1:05 PMTitan Pharmaceuticals: Submission Of Matters To A Vote Of Security Holders, Financial Statements And Exhibitscbonds.com - December 30 at 10:29 AMTitan Pharmaceuticals, Inc.: Titan Pharmaceuticals Announces Reverse Stock Split and Ratiofinanznachrichten.de - December 29 at 8:01 AMBarbie, the Titan submersible and everything else we Googled in 2023washingtonpost.com - December 28 at 8:29 PMTitan Pharmaceuticals Announces Reverse Stock Split and Ratiofinance.yahoo.com - December 28 at 8:29 PMUntitled Attack on Titan Codes (December 2023)twinfinite.net - December 27 at 3:54 PM2023 Nissan Titan XD Reviewautoblog.com - December 27 at 3:54 PMAttack on Titan Revolution Codes (December 2023)twinfinite.net - December 20 at 10:44 PMTitan Pharmaceuticals Announces Appointment of Dato' Seow Gim Shen and Brynner Chaim to the Company's Board of Directorsfinance.yahoo.com - October 16 at 8:58 PMMore presumed human remains recovered from imploded Titan submersibletoday.com - October 14 at 10:10 AMTitan Pharmaceuticals reports $9.5M private placement of convertible preferred stockseekingalpha.com - September 18 at 11:34 AMTitan Pharmaceuticals Announces $9.5 Million Private Placement of Convertible Preferred Stockfinance.yahoo.com - September 18 at 11:34 AMUnveiling Titan Pharmaceuticals (TTNP)'s Value: Is It Really Priced Right? A Comprehensive Guidefinance.yahoo.com - August 28 at 5:04 PMTitan Pharmaceuticals: Q2 Earnings Snapshotstamfordadvocate.com - August 15 at 5:27 PMTitan Pharmaceuticals (TTNP) Stock Soars on FDA Committee Treatment Approvalthestreet.com - August 13 at 6:28 PMTitan Pharmaceuticals sells certain ProNeura assets to Fedsonpharmabiz.com - July 29 at 5:54 AMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsInhibikase TherapeuticsNYSE:IKTInhibikase Therapeutics, Inc., a clinical-stage pharmaceutical company, develops therapeutics for Parkinson's disease and related disorders. Its lead product candidate is IkT-148009, a small molecule Abelson tyrosine kinase inhibitor, which is in Phase 2a clinical trials to the treatment of Parkinson's disease and gastrointestinal tract. The company is also developing IkT-001Pro, a prodrug of the anticancer agent imatinib mesylate to treat stable phase chronic myelogenous leukemia. Inhibikase Therapeutics, Inc. has research and development collaborations with Johns Hopkins University, Arizona State University, University of Bordeaux, and Michigan State University, as well as University of California; and a collaborative research and development agreement with Sphaera Pharma Pte. Ltd. The company was founded in 2008 and is headquartered in Atlanta, Georgia.OrganovoNASDAQ:ONVOOrganovo Holdings, Inc., a biotechnology company, focuses on developing 3D tissues that recapitulate key aspects of human disease. Its 3D human tissue platform includes its proprietary NovoGen Bioprinters, which are automated devices that enable the fabrication of 3D living tissues comprised mammalian cells; and related technologies for preparing bio-inks and bioprinting multicellular tissues with complex architecture. The company offers ExVive 3D bioprinted human liver tissue with distinct hepatocellular and non-parenchymal cell compartments. The company was incorporated in 2007 and is headquartered in San Diego, California.Rubius TherapeuticsNASDAQ:RUBYRubius Therapeutics, Inc., a biopharmaceutical company, focuses on the development of red cell therapeutics for the treatment of cancer and autoimmune diseases. The company was formerly known as VL26, Inc and as changed its name to Rubius Therapeutics, Inc. in 2015. Rubius Therapeutics, Inc. was incorporated in 2013 and is based in Foxborough, Massachusetts.Titan PharmaceuticalsNASDAQ:TTNPTitan Pharmaceuticals, Inc., a pharmaceutical company, develops therapeutics for the treatment of chronic diseases. It develops products based on ProNeura, a proprietary long-term drug delivery platform. The company offers Probuphine implant for the maintenance treatment of opioid use disorder in clinically stable patients in the United States, Canada, and the European Union. It also develops TP-2021 in combination with ProNeura technology for the treatment of chronic pruritus, a severe and debilitating condition defined as itching of the skin lasting longer than six weeks; Nalmefene implant program for the prevention of opioid relapse following detoxification of patients suffering opioid use disorder; and other programs, including HIV preventative therapeutic and a contraceptive from a single ProNeura implant for women and adolescent girls. The company was incorporated in 1992 and is based in South San Francisco, California. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.